
Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent
- If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging.
- Proven track record of [18F]-DCFPyL (branded as PYLARIFY® in the U.S.), with more than 100,000 prostate cancer patient scans performed in 2022 in the U.S.
PARIS, May 26, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) for
primary staging of patients with high-risk PCa prior to initial curative therapy and to localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent.
Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “This positive CHMP opinion for PYLCLARI® is an important step forward in our goal of redefining the experience of cancer through our trusted legacy in nuclear medicine. We are extremely pleased with the CHMP positive opinion and recommendation to grant a marketing authorization in Europe for PYLCLARI®, a diagnostic imaging medicine for the detection of prostate specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer, based on the Phase III PYTHON clinical trial conducted in Europe and the Phase III OSPREY and CONDOR clinical trials conducted in the U.S.”
Benoit Woessmer, PET Europe CEO at Curium added, “This CHMP positive opinion is a very important milestone for Curium, our customers, and their patients. Upon its approval, PYLCLARI® will become available across Europe to help patients along their prostate cancer journey. We are very excited to bring PYLCLARI® to the market and contribute to improving the set of diagnostic tools available to better diagnose and monitor prostate cancer. PSMA PET with PYLARIFY® is the standard of care in the U.S. We are looking forward to answering the high expectations of the nuclear medicine community when it comes to having the right tool reliably available to address this fast-growing pathology.”
Curium submitted its Marketing Authorization Application for Piflufolastat (18F) to the EMA in July 2022. The CHMP’s positive opinion on PYLCLARI® will be referred to the European Commission, which will deliver a final decision in approximately two months.
In the U.S., [18F]-DCFPyL was approved by the Food and Drug Administration (FDA) in May 2021 and is commercially available as PYLARIFY® (Piflufolastat F 18 Injection) and sold by Lantheus. In 2022, more than 100,000 patient scans using PSMA PET with PYLARIFY were performed.
About Curium
Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com
For more information:
Ross Bethell
VP, Head of Global Communications
communications@curiumpharma.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nokia Corporation: Repurchase of own shares on 26.09.202326.9.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 26 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 26.09.2023 Espoo, Finland – On 26 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL311,0543.56CEUX55,9623.57AQEU8,7573.55TQEX16,2273.57Total392,0003.56 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar
Sunstone IV hf. announces Consolidated Condensed Interim Financial Statements for the six months ended June 30, 202326.9.2023 19:56:38 CEST | Press release
Sunstone IV hf. Storhofdi 22-30, 110 Reykjavik, Iceland Sunstone IV hf. announces Consolidated Condensed Interim Financial Statements for the six months ended June 30, 2023 Consolidated condensed interim financial statements, for the six months ended June 30, 2023 of Sunstone IV hf. were approved at a Board of Directors meeting on 21 September 2023. The financial statements can be found on the Company’s website: https://www.mila.is/um-milu/fjarmal/sunstone-iv/ For more information please contact: Inga Helga Halldórudóttir Compliance officer Sunstone IV hf. ingah@mila.is
Nokia to bring semiconductor expertise to CHIPS and Science Act funded innovation hub26.9.2023 18:20:01 CEST | Press release
Press Release Nokia to bring semiconductor expertise to CHIPS and Science Act funded innovation hub Nokia will join a new innovation hub that seeks to expand U.S. global leadership in microelectronics technical development.The program will help reduce U.S. reliance on foreign microelectronics and safeguard supply chain risks, while ensuring access to cutting edge semiconductors for the Department of Defense. 26 September 2023 Murray Hill, New Jersey – Nokia today announced that it is part of the Northeast Microelectronics Coalition (NEMC) Hub, a regional innovation hub led by the Massachusetts Technology Collaborative (MassTech). The NEMC Hub was recently awarded funding to advance the microelectronics needs of the U.S. Department of Defense (DoD) from the "Creating Helpful Incentives to Produce Semiconductors (CHIPS) and Science Act." The funding award will establish a total of eight Microelectronics Commons regional innovation hubs and Core Facilities distributed across the United St
ABC arbitrage : Continuation of liquidity contract of ABC ARBITRAGE26.9.2023 18:00:00 CEST | Press release
Continuation of liquidity contract of ABC ARBITRAGE ABC ARBITRAGE informs that it will continue the liquidity contract with Kepler Cheuvreux, adding the following additional resources: 80,000 in cash (transfer executed on 21 September 2023). As a reminder : • the following resources appeared on the last half year statement on 30 June 2023 on the liquidity account: - 51,410 shares - € 111,829.43 - Number of executions on buy side on semester: 783 - Number of executions on sell side on semester: 1,120 - Traded volume on buy side on semester: 125,924 shares for € 781,516.85 - Traded volume on sell side on semester: 115,527 shares for € 719,846.14 • the following resources appeared on the liquidity account when the activity started: - 28,440 shares - € 49,007.93 The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice. Contacts : abc-arbitrage.com
ROBIT PLC: REPURCHASE OF OWN SHARES 26 SEPTEMBER 202326.9.2023 17:45:00 CEST | Press release
ROBIT PLC STOCK EXCHANGE RELEASE 26 SEPTEMBER 2023 AT 18.45 EEST ROBIT PLC: REPURCHASE OF OWN SHARES26 SEPTEMBER 2023 Robit PlcNasdaq Helsinki LtdDate26.9.2023Exchange transactionBUYShare trading codeROBITAmount, shares1765Average price / share, EUR1,453666Total cost, EUR2565,72 Robit Plc now holds a total of 17 479 shares including the shares repurchased on 26 September 2023. Detailed information concerning the repurchase is attached to this stock exchange release. On behalf of Robit Plc OP Corporate Bank Mikael Ahovuo Further information: Robit Plc Arto Halonen, Group CEO +358 40 028 0717 arto.halonen@robitgroup.com Distribution: Nasdaq Helsinki Ltd Key media www.robitgroup.com Robit is the specialist focused on high quality drilling consumables for the mining and construction markets globally to help you drill even Further. Faster. Robit strives to be the world’s number one drilling consumables company. Through our proven, high-quality Top Hammer, Down the Hole and Geotechnical prod